Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-93538 in Eosinophilic Esophagitis
NCT04753697Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Started Feb 2021; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04753697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753697.